NasdaqGS:CGONBiotechs
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
CG Oncology (CGON) has moved into focus after amending its planned stock offering to US$550 million from US$250 million, a sizeable raise that ties directly to ongoing clinical development and anticipated topline trial disclosures.
See our latest analysis for CG Oncology.
The latest stock offering news comes on top of strong share price momentum, with a 30 day share price return of 9.05%, a 90 day share price return of 68.53%, and a 1 year total shareholder return of about 3x. This suggests...